ストックスクリーナーアプリを入手
6.6254
4.44%
0.3254
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
(CRBP) Trading Report - news.stocktradersdaily.com
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth - Yahoo Finance
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP stock touches 52-week low at $4.64 amid sharp annual decline - Investing.com
CRBP stock touches 52-week low at $4.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Where are the Opportunities in (CRBP) - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $59.13 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles Schwab Investment Management Inc. Purchases 4,239 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence By Investing.com - Investing.com South Africa
Corbus begins Phase 1 trial for new obesity treatment CRB-913 By Investing.com - Investing.com South Africa
CRBP Stock Plummets to 52-Week Low of $5.65 Amid Market Turbulence - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - Quantisnow
Corbus begins Phase 1 trial for new obesity treatment CRB-913 - Investing.com
Corbus Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Corbus Pharmaceuticals to reduce board size post-annual meeting By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Corbus Pharmaceuticals to reduce board size post-annual meeting - Investing.com
Corbus Pharmaceuticals Announces Board Member Departure - TipRanks
CRBP stock touches 52-week low at $5.9 amid steep annual decline - Investing.com Australia
CRBP stock touches 52-week low at $5.9 amid steep annual decline By Investing.com - Investing.com South Africa
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) - Yahoo Finance
Corbus Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
Corbus Pharmaceuticals Appoints Ian Hodgson as COO - TipRanks
Corbus Pharmaceuticals appoints new COO - Investing.com
B. Riley Lifts Earnings Estimates for Corbus Pharmaceuticals - Defense World
HC Wainwright Issues Positive Estimate for CRBP Earnings - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Cut to $53.00 by Analysts at Jefferies Financial Group - MarketBeat
Lifesci Capital Has Optimistic Outlook of CRBP Q1 Earnings - Defense World
What is B. Riley’s Forecast for CRBP Q1 Earnings? - Defense World
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):